“We hope these data will support an EUA” (emergency use authorization) from the U.S. Food and Drug Administration, Regeneron Chief Scientific Officer George Yancopoulos said on a conference call. The treatment, REGN-COV2, is also being studied for use in hospitalized patients, and for prevention of infection in people who have been exposed to COVID-19. Regeneron declined to comment on when those trial results are expected. …read more
Source:: Yahoo Finance
